Skip to main content
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2004 Sep 2;4(11):3477–3484. doi: 10.1002/pmic.200400897

The use of proteomics in the discovery of serum biomarkers from patients with severe acute respiratory syndrome

Yi Ren 1,, Qing‐Yu He 2,3, Jianqing Fan 4, Brian Jones 5, Yuan Zhou 6, Yi Xie 1, Chung‐Yan Cheung 7, Adrian Wu 8, Jen‐Fu Chiu 3,6, J S Malik Peiris 7, Paul Kwong Hang Tam 1,9
PMCID: PMC7167722  PMID: 15378763

Abstract

Severe acute respiratory syndrome (SARS) is a new infectious disease with a global impact. Understanding its pathogenesis and developing specific diagnostic methods for its early diagnosis are crucial for the effective management and control of this disease. By using proteomic technology, truncated forms of α1‐antitrypsin (TF‐α1‐AT) were found to increase significantly and consistently in sera of SARS patients compared to control subjects. The result showed a sensitivity of 100% for SARS patients and a specificity of 92.8% for controls. Furthermore, the levels of these proteins significantly correlated with certain clinico‐pathological parameters. The dramatic increase in TF‐α1‐AT may be the result of degradation of α1‐AT. As α1‐AT plays an important role in the protection of lung function, its degradation may be an important factor in the pathogenesis of SARS. These findings indicate that increased TF‐α1‐AT may be therapeutically relevant, and may also be a useful biological marker for the diagnosis of SARS.

Keywords: α1‐antitrypsin, Biomarker, Complement 4, Serum amyloid A, Severe acute respiratory syndrome

References


Articles from Proteomics are provided here courtesy of Wiley

RESOURCES